A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

Nature Medicine

Volumn 21, Issue 1, 2015, Pages 27-36

  Finan, Brian ^a,b,c   Yang, Bin ^c,d   Ottaway, Nickki ^e   Smiley, David L ^c   Ma, Tao ^c,f   Clemmensen, Christoffer ^a,b   Chabenne, Joe ^c,g   Zhang, Lianshan ^d   Habegger, Kirk M ^h   Fischer, Katrin ^a,b   Campbell, Jonathan E ⁱ   Sandoval, Darleen ^e   Seeley, Randy J ^e   Bleicher, Konrad ^j   Uhles, Sabine ^j   Riboulet, William ^j   Funk, Jürgen ^j   Hertel, Cornelia ^j   Belli, Sara ^j   Sebokova, Elena ^j   Conde Knape, Karin ^j   Konkar, Anish ^j   Drucker, Daniel J ⁱ   Gelfanov, Vasily ^c   Pfluger, Paul T ^a,b   Müller, Timo D ^a,b   Perez Tilve, Diego ^e   DiMarchi, Richard D ^c   Tschöp, Matthias H ^a,b   more..

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INDIANA UNIVERSITY   (United States)

^d Marcadia Biotech   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f Beijing Hanmi Pharm   (China)

^g AIT Laboratories   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ MOUNT SINAI HOSPITAL   (Canada)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE GLUCAGON RECEPTOR TRIAGONIST; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; INCRETIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCOSE BLOOD LEVEL; INSULIN; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; DRUG EFFICACY; ENERGY EXPENDITURE; ENERGY METABOLISM; FATTY LIVER; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HYPOGLYCEMIA; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; RODENT; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; BIOSYNTHESIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; HEK293 CELL LINE; METABOLISM; SYNTHESIS;

RODENTIA;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HEK293 CELLS; HUMANS; INSULIN; MICE; OBESITY; PEPTIDES; RATS; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON; RODENTIA;

EID: 84925282923     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3761     Document Type: Article

References (36)

1. Speakman, J.R. & O'Rahilly, S. Fat: an evolving issue. Dis. Model. Mech. 5, 569-573 (2012).
2. Di Dalmazi, G., Vicennati, V., Pasquali, R. & Pagotto, U. The unrelenting fall of the pharmacological treatment of obesity. Endocrine 44, 598-609 (2013).
3. Rodgers, R.J., Tschop, M.H. & Wilding, J.P. Anti-obesity drugs: past, present and future. Dis. Model. Mech. 5, 621-626 (2012).
4. Gadde, K.M. et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377, 1341-1352 (2011).
5. Allison, D.B. et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20, 330-342 (2012).
6. Garvey, W.T. et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am. J. Clin. Nutr. 95, 297-308 (2012).
7. Fosgerau, K. et al. The novel GLP-1-gastrin dual agonist, ZP3022, increases beta-cell mass and prevents diabetes in db/db mice. Diabetes Obes. Metab. 15, 62-71 (2013).
8. Day, J.W. et al. A new glucagon and GLP-1 coagonist eliminates obesity in rodents. Nat. Chem. Biol. 5, 749-757 (2009).
9. Finan, B. et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 5, 209ra151 (2013).
10. Pocai, A. et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58, 2258-2266 (2009).
11. Finan, B. et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 18, 1847-1856 (2012).
12. Clemmensen, C. et al. GLP-1/glucagon co-agonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 63, 1422-1427 (2014).
13. Sadry, S.A. & Drucker, D.J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 9, 425-433 (2013).
14. Barrera, J.G., Sandoval, D.A., D'Alessio, D.A. & Seeley, R.J. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat. Rev. Endocrinol. 7, 507-516 (2011).
15. Campbell, J.E. & Drucker, D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819-837 (2013).
16. Habegger, K.M. et al. The metabolic actions of glucagon revisited. Nat. Rev. Endocrinol. 6, 689-697 (2010).
17. Habegger, K.M. et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62, 1453-1463 (2013).
18. Chabenne, J.R., DiMarchi, M.A., Gelfanov, V.M. & DiMarchi, R.D. Optimization of the native glucagon sequence for medicinal purposes. J. Diabetes Sci. Technol. 4, 1322-1331 (2010).
19. Ward, B. et al. Peptide lipidation stabilizes structure to enhance biological function. Mol. Metab. 2, 468-479 (2013).
20. Yip, R.G., Boylan, M.O., Kieffer, T.J. & Wolfe, M.M. Functional GIP receptors are present on adipocytes. Endocrinology 139, 4004-4007 (1998).
21. Panjwani, N. et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE-/-mice. Endocrinology 154, 127-139 (2013).
22. Patterson, J.T. et al. A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. ACS Chem. Biol. 6, 135-145 (2011).
23. European Medicines Agency. Assessment Report for Victoza; doc. ref. EMEA/379172/2009 (2009).
24. Bhat, V.K., Kerr, B.D., Vasu, S., Flatt, P.R. & Gault, V.A.A. DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice. Diabetologia 56, 1417-1424 (2013).
25. Gault, V.A., Bhat, V.K., Irwin, N. & Flatt, P.R. A novel GLP-1/glucagon hybrid peptide with triple-acting agonist activity at GIP, GLP-1 and glucagon receptors and therapeutic potential in high-fat-fed mice. J. Biol. Chem. 288, 35581-35591 (2013).
26. Miyawaki, K. et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8, 738-742 (2002).
27. Gelling, R.W. et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. USA 100, 1438-1443 (2003).
28. Day, J.W. et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers 98, 443-450 (2012).
29. Scrocchi, L.A. & Drucker, D.J. Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor-/- mice. Endocrinology 139, 3127-3132 (1998).
30. Kim, M. et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 19, 567-575 (2013).
31. Mukharji, A., Drucker, D.J., Charron, M.J. & Swoap, S.J. Oxyntomodulin increases intrinsic heart rate through the glucagon receptor. Physiol. Rep. 1, e00112 (2013).
32. Bhat, V.K., Kerr, B.D., Flatt, P.R. & Gault, V.A. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochem. Pharmacol. 85, 1655-1662 (2013).
33. Ionut, V., Burch, M., Youdim, A. & Bergman, R.N. Gastrointestinal hormones and bariatric surgery-induced weight loss. Obesity (Silver Spring) 21, 1093-1103 (2013).
34. Muller, T.D. et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J. Pept. Sci. 18, 383-393 (2012).
35. Bénardeau, A. et al. Effects of the dual PPAR-a agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat. Diabetes Obes. Metab. 15, 164-174 (2013).
36. Uhles, S. et al. Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic beta-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo. Diabetes Obes. Metab. 13, 326-336 (2011).